This technology includes a number of dimeric RGD peptides which been developed and labeled with various PET isotopes (1BF, 68Ga, and 64Cu) for imaging integrin expression in cancer, inflammation, rheumatoid arthritis, myocardial infarct, stroke and traumatic injury. A number of these peptides have been translated into clinic for diagnosis and therapy response monitoring.
This technology includes a method which enables high-speed, super-resolution microscopy at a very high signal-to-noise ratio (SNR), for biological applications within ~200 nm (the evanescent wave decay length) of a coverslip surface. Instant TIRF/SIM may be implemented simply by modifying and adding to the excitation optics that are already present within a conventional instant SIM design. We enforce TIRF excitation by removing all wave vectors that propagate into the objective lens at sub-critical angles.
This technology includes anti-PSMA antibody labeled with 177Lu, which has shown to be an effective treatment for prostate cancer. Several small molecules targeting PSMA were also evaluated in prostate cancer patients labeled with betta emitters such as 177Lu. The most common one is 177Lu-PSMA-617 which is under clinical evaluation in many countries. Usual treatment in patients in most clinical trials was composed of up to 3 cycles of 177Lu-PSMA-617.
This technology includes a method that extends fluorescence polarization imaging so that the dipole moment of a fluorescent dye may be excited regardless of its 3D orientation. By exciting the dipole from multiple directions, we ensure that excitation may occur even if the dipole is unfavorably oriented along the axial (propagation) axis. If the dye can be rigidly attached to the structure of interest, our method also enables the 3D orientation of the structure to be estimated accurately.
This technology includes a newly designed, truncated Evans Blue (EB) form which allows labeling with metal isotopes for nuclear imaging and radiotherapy. Unlike previous designs, this new form of truncated EB confers site specific mono-labeling of desired molecules. The newly designed truncated EB form can be conjugated to various molecules including small molecules, peptides, proteins and aptamers to improve blood half-life and tumor uptake, and confer better imaging, therapy and radiotherapy.
This technology includes a microscopy technique that produces super-resolution images from diffraction-limited images obtained from a line scanning confocal microscope. First, the operation of the confocal microscope is modified so that images with sparse line excitation are recorded. Second, these images are processed to increase resolution in one dimension. Third, by taking a series of such super-resolved images from a given sample type, a neural network may be trained to produce images with 1D super-resolution from new diffraction-limited images.
This technology includes a straightforward and versatile nanotechnology-based approach for in situ therapeutic vaccination that exploits a primary tumor as a vaccine depot to initiate robust personalized anti-tumor immune responses.